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Abstract
Background In patients with Crohn’s disease (CD), luminal disease activity paralleled by perianal fistulas may seriously 
impair health-related quality of life (HRQoL). Health utility values are not available from patients with CD that reflect the 
health loss associated with both luminal and perianal CD.
Objective To generate utilities for luminal and concomitant perianal fistulising CD health states directly from patients and 
from members of the general public.
Methods A cross-sectional survey was undertaken enrolling CD patients and a convenience sample of members of the general 
population. Respondents were asked to evaluate four common CD heath states [severe luminal disease (sCD), mild luminal 
disease (mCD), severe luminal disease with active perianal fistulas (sPFCD), and mild luminal disease with active perianal 
fistulas (mPFCD)] by 10-year time trade-off (TTO). In addition, patients assessed their current HRQoL by the TTO method.
Results Responses of 206 patients (40.8% with perianal fistulas) and 221 members of the general population were analysed. 
Mean ± SD utilities among patients for sPFCD, sCD, mPFCD and mCD states were 0.69 ± 0.33, 0.73 ± 0.31, 0.80 ± 0.29 and 
0.87 ± 0.26. Corresponding values in the general public were: 0.59 ± 0.31, 0.65 ± 0.29, 0.80 ± 0.26 and 0.88 ± 0.25. Patients 
with active perianal fistulas, previous non-resection surgeries, and higher pain intensity scores valued their current health 
as worse (p < 0.05).
Conclusions TTO is a feasible method to assess HRQoL in patients with perianal fistulising disease, often not captured by 
health status questionnaires. Utilities from this study are intended to support the optimization of treatment-related decision 
making in patients with luminal disease paralleled by active perianal fistulas.
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Introduction
Crohn’s disease (CD) is a chronic inflammatory disorder 
of the gastrointestinal tract, often characterised by poten-
tially debilitating symptoms such as abdominal pain, rectal 
bleeding, diarrhoea, fatigue and urgency [1]. Perianal fis-
tulising Crohn’s disease (PFCD) is a common manifesta-
tion of CD affecting up to 40% of all patients [2]. In the 
majority of cases, perianal disease is paralleled by luminal 
disease activity. Symptoms of PFCD include pain, scarring, 
discharge, faecal incontinence and sexual difficulties. In 
addition to physical symptoms associated with CD, there 
may be adverse psychosocial effects [3, 4]. The resulting 
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morbidity may seriously compromise health-related quality 
of life (HRQoL) and employment status of patients [5–7]. 
Despite the large burden of disease, HRQoL in PFCD has 
been less documented compared to luminal CD [8–10].
Few HRQoL studies have elicited health utilities for CD 
health states using a direct method [11]. Utilities are values 
measured on a cardinal scale anchored on 0 (= death) and 
1 (= full health), which measure the impact of an illness on 
HRQoL [12, 13]. These utilities are required in cost-effec-
tiveness analyses to calculate health benefits of a treatment 
expressed as quality-adjusted life years (QALYs). In the past 
2 decades, biological drugs revolutionised the treatment of 
both luminal and fistulising CD [14, 15]; nevertheless, no 
reliable directly elicited health utilities are present for the 
cost-effectiveness analyses of biological drugs [16, 17].
Utility studies in CD were mostly conducted about 2 
decades ago before or in the early era of biological drugs 
[18–20], often had a low sample size (< 50 patients) [18, 
20, 21], concerned only luminal disease but not PFCD [19, 
20], or suffered from a number of methodological short-
comings [21]. A very recent study from the UK used both 
patients and a general population sample to derive utilities 
for various PFCD health states [22]. In this study, luminal 
disease severity was constant for all health states, and the 
study focused on surgical outcomes of perianal fistulas. The 
utilities elicited may be less useful for cost-effectiveness 
models of biological drugs that are indicated to be effec-
tive for treating both luminal and PFCD. Therefore, utilities 
reflecting the health loss associated with luminal and con-
comitant perianal disease are needed.
The present study was designed to (1) generate utilities 
for common CD health states featuring luminal or luminal 
and concomitant perianal disease from the perspective of 
patients and members of the general public; (2) compare 
utilities for luminal CD to those when parallel perianal 
symptoms are present; (3) explore the impact of perspec-
tives on health utilities, and (4) determine whether utilities 
are related to respondents’ demographics, health status or 
clinical characteristics.
Methods
Study design
Two cross-sectional surveys were undertaken. First, a paper-
based survey was conducted with patients diagnosed with 
CD regardless of having perianal fistulising disease. The 
second, Internet-based, survey included members of the gen-
eral population. Permission for conducting the study was 
granted by the National Scientific and Ethical Committee 
(Reference no. 49548-4/2016/EKU). An informed consent 
form was signed by all participants.
Data collection: patient survey
Data were collected between October 2016 and September 
2017. Consecutive outpatients over 18 years from three aca-
demic gastroenterology departments and an inflammatory 
bowel diseases (IBD) centre in Hungary were enrolled in the 
study. The survey comprised of a paper-based questionnaire, 
the first part of which was completed by the patients, and 
the second by their gastroenterologist. Patients were asked 
about their socio-demographic characteristics and health sta-
tus. CD-related pain intensity was recorded on a horizontal 
visual analogue scale (VAS) with the endpoints of ‘no pain 
at all’ (= 0) and ‘pain as bad as it could be’ (= 10).
In the second part of the survey, gastroenterologists pro-
vided data about the medical history, clinical characteristics 
and treatments of their patients. Gastroenterologists assessed 
disease severity using Crohn’s Disease Activity Index 
(CDAI) and Perianal Disease Activity Index (PDAI) [23, 
24]. The CDAI is primarily based on a list of clinical symp-
toms or laboratory findings in the past 7 days. CDAI total 
scores range from 0 to 600, where a higher score represents 
a more severe disease. The PDAI includes five items (i.e., 
discharge, pain/restriction of activities, restriction of sexual 
activity, type of perianal disease and degree of induration). 
Total PDAI score varies between 0 and 20, where a score 
of ≤ 4 identifies an inactive disease, whereas a PDAI of > 4 
suggests an active fistulising disease [24, 25].
Data collection: general population survey
Internet-based questionnaires were completed between 
November 2017 and March 2018. A convenience sample 
of the general population (aged ≥ 18 years) was recruited 
from the campus of Corvinus University of Budapest to par-
ticipate in the survey. Participation was voluntary, anony-
mous and no remuneration was offered. The questionnaire 
collected data on socio-demographic characteristics of the 
respondents as well as their prior knowledge about CD (e.g., 
have known someone with CD). All questions of the online 
survey were mandatory, so respondents could not proceed 
to the next question without answering the previous one.
Utility assessment
Health state vignettes
Four health state vignettes were designed: severe luminal 
disease (sCD), mild luminal disease (mCD), severe lumi-
nal disease with active perianal fistulas (sPFCD), and mild 
luminal disease with active perianal fistulas (mPFCD). The 
descriptions were developed by a group of IBD experts 
and health economists experienced in utility assessment. 
The final vignettes combined a description of living with 
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CD including intestinal symptoms, abdominal pain, fistula 
symptoms, sleep, extraintestinal symptoms, eating, work/
school, and leisure and social activities (Supplementary 
material S1). The descriptions were presented from a first-
person perspective in a table format, as an earlier study 
reported that patients strongly prefer this format over nar-
rative health state descriptions [26]. Subjects were asked 
to read the descriptions carefully and imagine living in the 
condition described.
Time trade‑off (TTO)
All TTO tasks were self-administered. The TTO method 
elicits HRQoL or utility values for imperfect health states by 
asking respondents to make a trade off between quality and 
length of life [13]. We opted to use a 10-year time frame, as 
this is most commonly used for the valuation of health states 
[27–32]. Individuals were asked to imagine living in the CD 
health states as described in the vignettes for the ensuing 
10 years, followed by death. Then they had to indicate how 
many life years they would give up to regain full health. 
Respondents were offered to choose from 20 predefined, 
tradable amounts of time (0 years, 6 months, 1 year,…, 
9 years, 9.5 years and 10 years). An example for a TTO 
valuation task is provided in Supplementary material S2. 
The four health states were randomized within respondents 
both for patients and the general population sample.
TTO utilities were calculated according to the following 
formula:
Suppose, for example, a respondent indicated to exchange 
2 years, yielding U = (10 − 2)/10 = 0.8. Therefore, TTO 
utilities in this study were anchored on 0 (death) and 1 (full 
health).
Statistical analyses
Socio-demographic and clinical characteristics of the patient 
and general population groups were compared using a Stu-
dent’s t test and χ2 test. All non-missing TTO responses were 
included in the primary data analysis. Descriptive statistics 
(mean, median, standard deviation and IQR) of utilities 
were computed. A paired t test was used to test the differ-
ence between TTO utilities for hypothetical health states. 
TTO utilities within subgroups of patients were compared 
by Student’s t test or analysis of variance (ANOVA), where 
applicable.
We performed random-effects linear regression models 
to explore demographic, clinical and other possible pre-
dictors of utilities for hypothetical health states. Before 
Utility = 1 − disutility = 1 −
participant�s answer
10 years
.
running the models, the following participants were 
excluded: (1) non-traders (i.e., who valued all health states 
equal to full health), (2) who indicated the same value for 
all health states, (3) who had more than two missing TTO 
responses out of the four hypothetical health states and 
(4) who indicated a logical inconsistency (i.e., utilities 
for sCD > mCD or sPFCD > mPFCD or sPFCD > mCD). 
Determinants of utilities for current health were analysed 
by ordinary least squares regression. No exclusions were 
applied before the regression analysis of utilities for cur-
rent health. All the statistics were two-sided, and p < 0.05 
was considered statistically significant. Data were analysed 
using Stata 13 (College Station, TX, USA: StataCorp LP).
Results
Demographic and clinical characteristics 
of the study populations
Overall, 206 patients with CD and 221 adults from the 
general population participated in the study. There were a 
total of 41 (4.0%) missing TTO responses from patients: 
n = 7 for sCD, n = 7 for mCD, n = 9 for sPFCD, n = 13 for 
mPFCD and n = 5 for current health. There were no miss-
ing responses in the general population sample.
Table 1 provides demographic characteristics of the 
study participants. Patients and members of the general 
population were similar with respect to demographics. 
Patients were on average 3 years younger compared to the 
general population. There was a slight male predominance 
in both groups. A total of 28.8% of patients had a tertiary 
education, while this rate was 56.1% for the general popu-
lation sample. The distribution of participants in the two 
groups was more or less balanced according to employ-
ment status and place of residence within the country.
More than two-thirds of the general population sample 
have never heard about CD. Altogether, 16.7% have read 
or heard about CD from the internet/media/newspapers, 
8.6% learned about CD as they were being employed in 
healthcare, 4.1% had a family member or acquaintance 
suffering from CD and 3.6% indicated to be diagnosed 
with CD (Table 1).
Table  2 presents the clinical characteristics of 
the patient sample. Mean ± SD disease duration was 
10.5 ± 6.3 years. Eighty-four patients (41%) had perianal 
fistulas, 36.1% of them being active. Extraintestinal mani-
festations were present in 57 patients (27.7%). At the time 
of the survey, 66% received biological therapy (infliximab 
47.6%, adalimumab 17.5% and vedolizumab 1.9%).
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Utility results
Table 3 shows the mean utilities derived from the two groups 
for the hypothetical health states as well as current health 
for patients. Among patients, mean utilities were 0.69 ± 0.33 
for sPFCD, 0.73 ± 0.31 for sCD, 0.80 ± 0.29 for mPFCD and 
0.87 ± 0.26 for mCD health state. Corresponding values in 
the general public were as follows: 0.59 ± 0.31, 0.65 ± 0.29, 
0.80 ± 0.26 and 0.88 ± 0.25. In both groups, significant dif-
ferences were observed across all hypothetical health states 
(p < 0.001).
For each health state, the proportion of patients not will-
ing to give up any time (i.e., ‘1’ answers) is presented in 
Table 3. Among patients, this rate ranged from 27.9% for 
Table 1  Demographics and general health in the study populations
a One person may have heard about it from multiple sources
CD Crohn’s disease, N/A not applicable
Variables Mean (SD) or N (%) p value
Patients with CD 
(n = 206)
General population sample 
(n = 221)
Sex
 Female 93 (45.1%) 71 (32.1%) < 0.001
 Male 113 (54.9%) 150 (67.9%)
Age (years) 34.7 (10.5) 37.3 (15.5) < 0.001
Age groups (years)
 18–24 37 (18.0%) 75 (33.9%) < 0.001
 25–34 71 (34.5%) 39 (17.6%)
 35–44 59 (28.6%) 27 (12.2%)
 ≥ 45 39 (18.9%) 80 (36.2%)
Education (n = 1)
 Primary school 14 (6.8%) 4 (1.8%) < 0.001
 Secondary school 132 (71.2%) 93 (42.1%)
 College/university 59 (28.8%) 124 (56.1%)
Employment
 Student 25 (12.1%) 63 (28.5%) < 0.001
 Full time 110 (53.4%) 100 (45.2%) 0.092
 Part time 30 (14.6%) 21 (9.5%) 0.107
 Unemployed 11 (5.3%) 9 (4.1%) 0.536
 Retired 3 (1.5%) 12 (5.4%) 0.026
 Disability pensioner 49 (23.8%) 4 (1.8%) < 0.001
 Other 15 (7.3%) 12 (5.4%) 0.424
Place of residence
 Capital (Budapest) 45 (21.8%) 102 (46.2%) < 0.001
 County town 34 (16.5%) 24 (10.9%) 0.089
 Smaller town 81 (39.3%) 63 (28.5%) 0.018
 Village 46 (22.3%) 32 (14.5%) 0.036
Subjective life expectancy (years) 76.3 (12.4) 79.0 (11.0) 0.019
Prior experiences with CD of participants from the general population
 Have never heard about it N/A 153 (69.2%) N/A
 Have heard about  ita N/A 68 (30.8%) N/A
  Have been diagnosed with CD N/A 8 (3.6%) N/A
  Have a family member or acquaintance with CD N/A 9 (4.1%) N/A
  Doctor N/A 9 (4.1%) N/A
  Employed in healthcare (but not a doctor) N/A 10 (4.5%) N/A
  Medical student N/A 1 (0.5%) N/A
  Read/heard about it from the Internet/media/newspaper N/A 37 (16.7%) N/A
  Other N/A 5 (2.3%) N/A
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sPFCD to 58.3% for mCD. In contrast, these figures were 
9.0% and 55.9% for the general public. There were 50 
patients (24.3%) and 26 members of the general population 
(11.8%) who were non-traders (i.e., rated all health states 
equal to ‘1’, including their current health for patients). 
Overall, 4.1%, 2.0%, 2.6% and 1.5% rated the sPFCD, sCD, 
mPFCD and mCD to be as bad as dead (utility = 0).
Mean TTO utilities from patients were higher for the 
two severe health states compared to the general public 
(p < 0.01). There was no statistically significant difference 
in TTO scores for the two mild health states between the 
two groups.
Table 4 demonstrates the mean current health state utility 
for subgroups of patients. Mean utility for patients’ current 
health was 0.83 ± 0.28. The TTO method well discriminated 
between patients with active perianal fistulas and those with 
inactive or no fistulas (0.67 ± 0.37 vs. 0.86 ± 0.26; p = 0.013). 
Previous non-resection (0.76 ± 0.33) or both resection and 
non-resection (0.75 ± 0.37) surgeries were associated with 
lower mean TTO values (p = 0.023). Differences between 
groups based on CDAI score also showed a trend towards 
statistical significance.
Multivariate analysis of predictors of utilities
Supplementary material S3 demonstrates the results 
of regression models about predictors of TTO utilities. 
Patients’ utilities for the hypothetical health states were 
decreased by 0.012 with 1-point increase in body mass index 
(BMI) (p = 0.005). One-point increase in disease severity on 
CDAI resulted in a 0.001 decrease in utilities (p = 0.036). 
Employment status of patients had a significant impact on 
utilities, those working full time indicated lower values by 
0.071 (p = 0.020).
With respect to patients’ current health, each 1-point 
increase in pain intensity on a VAS (scale range 0–10) was 
associated with a 0.032 decrease in TTO utilities (p < 0.001). 
Patients who previously had a non-resection surgery due 
to CD rated hypothetical health states to 0.095 lower 
(p = 0.015). Patients who were retired valued their current 
health utility lower by 0.176, while those who were students 
gave higher values by, on average, 0.106.
Among members of the general public, TTO values for 
hypothetical health states increased by 0.002 with every 
1-year increase in age and by 0.003 with every 1-year 
Table 2  Clinical characteristics 
of CD patients (n = 206)
BMI body mass index, CD Crohn’s disease, CDAI Crohn’s Disease Activity Index, PDAI Perianal Disease 
Activity Index, VAS visual analogue scale
a Overall, 33 patients had both resection and non-resection surgeries
b Perianal fistula surgery, strictureplasty or abscess drainage
Mean (SD) or N (%)
Body mass index, BMI (kg/m2) (missing n = 2) 23.4 (4.3)
 Underweight (BMI > 18.5) 22 (10.8%)
 Normal (BMI 18.5–24.9) 111 (54.4%)
 Overweight (BMI 25.0–29.9) 57 (27.9%)
 Obesity (BMI > 30) 14 (6.9%)
Extraintestinal manifestations 57 (27.7%)
Disease severity: CDAI (0–600)  110.5 (77.0)
 Symptomatic remission (CDAI < 150) 156 (75.7%)
 Mild (CDAI 150–219) 32 (15.5%)
 Moderate to severe (CDAI 220 ≤) 18 (8.7%)
Perianal fistula severity: PDAI (0–20) (missing n = 1) 3.68 (2.29)
 Inactive (PDAI ≤ 4) 53 (63.9%)
 Active (PDAI > 4) 30 (36.1%)
Pain
 Pain VAS (0–100) 24.7 (23.9)
Current treatment
 None 3 (1.5%)
 Systemic non-biological 67 (32.5%)
 Biological 136 (66.0%)
Previous surgeries due to  CDa
 None 87 (42.2%)
 Resection surgery 66 (32.0%)
 Non-resection  surgeryb 86 (41.7%)
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increase in subjective life expectancy (p = 0.018). Peo-
ple who had a family member or acquaintance diagnosed 
with CD valued health states higher (+ 0.111, p = 0.043), 
while disability pensioners rated them to be lower by 0.174 
(p = 0.021).
Discussion
Main findings
This study evaluated individual preferences for different 
health states of CD using patients and a convenience sam-
ple from the Hungarian general population. The mean TTO 
values ranged between 0.69 and 0.88 derived from patients, 
and between 0.59 and 0.88 from the general population. In 
both groups, utilities for health states of severe and mild 
fistulising disease were significantly lower compared with 
health states describing the same luminal disease severity 
but with no concomitant perianal fistula symptoms. Patients 
assigned significantly higher values to the two health states 
of mild luminal severity than the general population, but 
this was not true for the severe health states. Patients with 
active perianal fistulas valued their current health much 
lower compared to those with inactive or no fistulas. Higher 
pain intensity experienced along with previous non-resection 
surgeries including perianal fistula surgery, strictureplasty 
and abscess drainage, were important predictors of reporting 
lower utilities for current health.
Comparison with other studies
Our results concur with findings from previous studies indi-
cating that perianal fistulas have a considerable impact on 
HRQoL [5]. Similarly to our study, Longworth et al. [22] 
used a 10-year time frame to assess TTO utilities for perianal 
fistulising health states in the UK. In their study, patients and 
the general public valued sPFCD health state to a mean of 
0.38 and 0.43, while mPFCD resulted in a mean of 0.58 and 
0.66, respectively. In comparison, we found higher mean 
utilities for both sPFCD (patients: 0.69 and general public: 
0.59) and mPFCD (both patients and general population: 
0.80). The differences may be attributable to the different 
patient populations in terms of disease characteristics and 
severity as well as to the methodological variations of TTO 
between the two studies. For instance, the UK study [22] 
employed different health state vignettes and allowed to 
value health states worse than dead.
Strengths and limitations
This is the largest study involving patients to directly elicit 
utilities for CD health states. Furthermore, compared to Ta
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previous studies, health state vignettes used in the pre-
sent study were more comprehensive featuring all aspects 
of HRQoL that may be relevant to CD patients. Another 
strength is the heterogeneous patient population recruited 
with regard to demographic as well as clinical characteris-
tics, which satisfies the purpose of this valuation study. The 
study has limitations as well. First, two-thirds of the patients 
were treated with biological drugs and, as a result, they were 
in a relatively good health state. Second, there were differ-
ences in socio-demographic characteristics such as age and 
educational background between patients and the general 
population sample. Furthermore, our sample was on aver-
age younger, and had a higher proportion of male and highly 
educated participants compared to a nationally representa-
tive sample of the Hungarian general population (mean age 
42 years, males 47%, college/university graduates 21%) [33].
Practical implications
The TTO seems to be superior to indirect utility assess-
ment when it comes to PFCD. As shown by earlier studies, 
the EQ-5D-3L or EQ-5D-5L questionnaires could not dis-
tinguish between subgroups of CD patients based on peria-
nal disease [6, 34]. We found that the 10-year TTO method 
discriminated well between HRQoL of patients with active 
and inactive or no perianal fistulas. In cost-effectiveness 
analyses of treatments for PFCD, directly elicited utili-
ties can be recommended to be used to calculate QALYs. 
Before this study, in absence of relevant and reliable utility 
data specifically for PFCD, all published cost-effectiveness 
analyses of biological drugs relied on either luminal CD 
results or unpublished data such as expert opinion [35–37]. 
Our results fill in the gap in literature by providing robust 
health utilities from both patient and general population 
perspectives for the economic evaluations of biological 
drugs for CD.
In many countries including the US, Canada, the UK, 
the Netherlands and Hungary a general population per-
spective is recommended in the context of economic 
evaluations, while other countries, such as Sweden, rec-
ommend the patient perspective [38–42]. There is an 
increasing body of literature arguing that utilities based 
on both patient and general public preferences should be 
considered in health technology assessment [43–46]. A 
result with direct impact on cost-effectiveness studies of 
our study is that the differences in utilities between the two 
severe and mild states were found to be smaller for patients 
compared to those among members of the general popu-
lation. This implies that using utilities reflecting patient 
preferences in cost-effectiveness analyses may reduce the 
QALY gain associated with therapy.
The assessment of HRQoL is advocated in guidelines for 
the management of PFCD by professional societies such as 
the European Crohn’s and Colitis Organisation (ECCO) and 
the American College of Gastroenterology (ACG) [47–49]. 
However, currently there is no validated, disease-specific, 
patient-derived HRQoL tool for PFCD. Development of 
such an outcome measure, Crohn’s Anal Fistula Quality of 
Life (CAF-QoL) is underway [50], although, the final ver-
sion was not available at the time this manuscript was writ-
ten. Importantly, we found that pain intensity has a large 
impact on HRQoL in patients with CD. Current ECCO and 
ACG guidelines recommend measuring abdominal pain as a 
part of the CDAI score. Our findings point out that thorough 
pain assessment would be essential in improving patients’ 
HRQoL.
Table 4  TTO utilities for 
current health in subgroups of 
patients (n = 201)
CD Crohn’s disease, CDAI Crohn’s Disease Activity Index, PDAI Perianal Disease Activity Index, TTO 
time trade-off
Variables Groups N Mean (SD) p value
Disease severity Symptomatic remission (CDAI < 150) 153 0.85 (0.27) 0.086
Mild (CDAI 150–219) 31 0.84 (0.33)
Moderate to severe (CDAI 220 ≤) 17 0.69 (0.34)
Perianal fistulas Inactive (PDAI ≤ 4) or no 172 0.86 (0.26) 0.013
Active (PDAI > 4) 29 0.67 (0.37)
Extraintestinal manifestations No 146 0.85 (0.26) 0.858
Yes 55 0.82 (0.29)
Current treatment Non-biological 66 0.87 (0.25) 0.139
Biological 132 0.81 (0.30)
Previous surgeries due to CD None 86 0.89 (0.20) 0.023
Resection 31 0.87 (0.26)
Non-resection 51 0.76 (0.33)
Both 33 0.75 (0.37)
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Conclusions
Overall, the results of this study well reflect the severity 
of different health states of CD, and highlight the addi-
tional HRQoL burden of living with perianal fistulising 
disease. It seems that the TTO method offers an accurate 
assessment of HRQoL in patients with PFCD, often not 
captured by health status questionnaires. Utilities from the 
present study are intended to support the optimization of 
treatment-related decision making in patients with luminal 
disease paralleled by active perianal fistulas and to estab-
lish a solid basis for cost-effectiveness analyses to compare 
treatment strategies.
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